Abstract
Hormones play a significant role in the pathogenesis of acne vulgaris. As such, combined hormonal contraceptives (CHCs) have been used to reduce acne severity. CHCs are not without risk, and more information is needed about serious adverse events (AE) and venous thromboembolism (VTE) risk due to CHC use in acne patients. Using data from FDA Adverse Events Reporting System, we examined the relative risk of AEs and VTE in patients prescribed CHCs for acne versus all other indications. We expected the cohort of women taking CHCs for acne reduction to be younger and have fewer comorbid risk factors for VTE, and thus that it would have a lower risk of AEs and VTE.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
